Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review

The optimal therapeutic strategy for locally advanced pancreatic cancer patients (LAPC) has not yet been established. Our aim is to evaluate how surgery after neoadjuvant treatment with either FOLFIRINOX (FFN) or Gemcitabine-NabPaclitaxel (GemNab) affects the clinical outcome in these patients. LAPC...

Full description

Bibliographic Details
Main Authors: Fabiana Napolitano, Luigi Formisano, Alessandro Giardino, Roberto Girelli, Alberto Servetto, Antonio Santaniello, Francesca Foschini, Roberta Marciano, Eleonora Mozzillo, Anna Chiara Carratù, Priscilla Cascetta, Pietro De Placido, Sabino De Placido, Roberto Bianco
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Cancers
Subjects:
LAPC
locally advanced pancreatic cancer
FOLFIRINOX
Gemcitabine Nab-Paclitaxel
neoadjuvant chemotherapy
NACT
conversion therapy
Online Access:https://www.mdpi.com/2072-6694/11/7/981

Similar Items

Similar Items